Royal Emerald Pharmaceuticals has applied to become a registered importer of certain controlled substances, specifically immature plants, which they intend to use for cultivating marijuana. The plants will be developed into botanical raw materials or Active Pharmaceutical Ingredients for approved medical, scientific, research, or industrial purposes. The application, submitted to the Drug Enforcement Administration (DEA), excludes importing FDA-approved or non-approved finished dosage forms intended for commercial sale. Comments or objections regarding this application can be submitted electronically until May 27, 2025.
Simple Explanation
Royal Emerald Pharmaceuticals wants permission to bring in young plants to grow so they can be turned into medicine or used for science. People can write in with any concerns or questions until May 27, 2025.